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A  novel  stability-indicating  reversed  phase  high  performance  liquid  chromatographic  (RP-HPLC)  method
for the simultaneous  assay  of  betamethasone-17-valerate,  fusidic  acid  and  potassium  sorbate  as  well  as
methyl-  and propylparaben  in  a topical  cream  preparation  has  been  developed.  A  100  mm  × 3.0  mm  ID.
Ascentis  Express  C18  column  maintained  at 30 ◦C  and  UV detection  at  240  nm  were  used.  A  gradient  pro-
gramme  was  employed  at a flow-rate  of  0.75  ml/min.  Mobile  phase  A  comprised  of  an  83:17  (v/v)  mixture
of  acetonitrile  and  methanol  and mobile  phase  B of  a 10 g/l  solution  of  85%  phosphoric  acid  in  purifiedeywords:
PLC
usidic acid
etamethasone-17-valerate
reservatives
evelopment
water.  The  method  has  been  validated  according  to current  International  Conference  on  Harmonisation
(ICH)  guidelines  and  applied  during  formulation  development  and  stability  studies.  The  procedure  has
been  shown  to be stability-indicating  for  the topical  cream.
©  2014  Elsevier  B.V.  All  rights  reserved.alidation
. Introduction
Inflamed skin conditions, such as eczema and dermatitis, can be
urther complicated by bacterial infections. For this reason, a topical
ream preparation containing the active pharmaceutical ingredi-
nts (APIs) betamethasone-17-valerate and fusidic acid as well as
he preservative compounds potassium sorbate, methylparaben
nd propylparaben (Fig. 1) has been developed.
Betamethasone-17-valerate (BV) is a potent corticosteroid with
nti-inflammatory properties applied topically for the treatment of
 variety of skin conditions, including eczema, atopic dermatitis and
soriasis [1] where it helps to relieve associated symptoms such as
edema and itching. Fusidic acid (FA) is a bacteriostatic antibiotic
ith steroid structure first isolated from the fermentation broth of
usidium coccineum by Godtfredsen et al. at the laboratories of Leo
harmaceutical Products in 1962 [2]. It is used for the treatment
f Gram-positive bacterial infections, particularly those caused by
taphylococcus species. It has regained popularity in recent years
∗ Corresponding author. Tel.: +49 34954/247 414.
E-mail address: jonathan.byrne@mibegmbh.de (J. Byrne).
ttp://dx.doi.org/10.1016/j.jpba.2014.03.005
731-7085/© 2014 Elsevier B.V. All rights reserved.due to its effectiveness in the treatment of methicillin-resistant
Staphylococcus aureus (MRSA) [3,4].
Potassium sorbate (PS) and both methyl- and propylparaben
(MP, PP) are antimicrobial substances, found in many pharmaceu-
tical and cosmetic preparations, which are effective against fungi
and Gram-positive bacteria [5]. Their function is to ensure that
microbiological purity is maintained throughout the shelf-life of
the product.
According to current guidelines [6,7], APIs and preservatives in
finished pharmaceutical products must be quantified as a general
quality control requirement during both release and shelf-life test-
ing. This is in order to demonstrate an acceptable level of quality
throughout the life-cycle of the pharmaceutical product. Initially,
the stability of trial batches must be determined during the for-
mulation development phase, necessitating the employment of a
stability-indicating analytical procedure. In the past, it was com-
mon  in analytical laboratories to have several individual HPLC
procedures for the separate analysis of APIs and preservatives in the
same finished formulation. In recent times, however, there appears
to be a trend towards developing a single procedure for the analy-
sis of all components in a single run. Examples include Shaikh et al.
[8], who developed a procedure for the simultaneous quantitation
of chlorocresol, mometasone furoate and fusidic acid in a topical
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Fig. 1. Chemical structures: M
ream with a run time of 8 min, and Goswami et al. [9], who devel-
ped a procedure for the analysis of halometasone, fusidic acid,
ethylparaben and propylparaben in a single run. This trend has
ost likely been driven by advances in analytical technology, such
s UPLC and more efficient, more selective analytical columns, as
ell as environmental awareness issues and cost efficiency.
From the outset the aim of the current analytical development
as to employ a single method for the analysis of all compounds.
owever, none of the analytical methods reported in the literature
re suitable for the simultaneous analysis of the 5 components of
nterest in a single chromatographic run. The majority of reported
ethods are only suitable for the analysis of a maximum of 1 or 2
f the compounds of interest [10,11] and are often based on poorly
elective procedures such as UV–vis spectrophotometry [12] or
tomic absorption spectrometry [13] which can no longer be con-
idered state-of-the-art and/or stability-indicating. Consequently,
t was necessary to develop a novel procedure for the analysis of
ll five components. The simultaneous analysis with the aid of a
ingle HPLC run would allow for a much more cost-effective and
ess time-consuming analysis of cream samples.
In this paper the development of a novel stability-indicating
P-HPLC method for the simultaneous assay of fusidic acid,
etamethasone-17-valerate and potassium sorbate, as well as
ethyl- and propylparaben in a topical cream preparation is
eported. The method has been validated according to cur-
ent International Conference on Harmonisation (ICH) guidelines
nd applied to development formulations and finished product
amples.
. Materials and methods.1. Reagents
Fusidic acid hemihydrate and betamethasone-17-valerate
ere purchased from OJSC Biosintez (Penza, Russia) and CrystalP (b), PS (c), BV (d) and FA (e).
Pharma (Valladolid, Spain), respectively. Potassium sorbate was
obtained from Merck (Darmstadt, Germany) and both methyl- and
propylparaben were purchased from Clariant (Pontypridd, UK). All
compounds were of Ph. Eur. or cosmetic grade.
Gradient grade methanol and acetonitrile were purchased from
VWR  International GmbH (Darmstadt, Germany). Purified water
was obtained from the in-house purification system at mibe GmbH
Arzneimittel (Brehna, Germany). Phosphoric acid (85%, analysis
grade) was  purchased from Merck (Darmstadt, Germany). All cream
samples were provided by mibe GmbH Arzneimittel.
2.2. Instrumentation
Shimadzu Prominence HPLC Systems (Shimadzu, Japan) were
used for method development and validation. The HPLC systems
were equipped with a binary pump (LC-20AD), a temperature-
controlled auto-sampler (SIL-20ACHT), a temperature-controlled
column compartment (CTO-20AC) as well as an on-line degasser
(DGU-20A5) and a photo-diode-array detector (SPD-M20A). The
software used was SHIMADZU LC solution version 1.24 SP1.
2.3. Chromatographic conditions and sample preparation
The HPLC column used was the Ascentis Express (Fused-Core®),
C18, 100 × 3.0 mm ID, with 2.7 m particles (Supelco®, Bellefonte,
USA) and a suitable guard-column. Mobile phase A comprised of an
83:17 (v/v) mixture of acetonitrile and methanol and mobile phase
B of a 10 g/l mixture of phosphoric acid (85%) in purified water.
A gradient elution programme was employed (Table 1) with a
mobile phase flow-rate of 0.75 ml/min. The column-oven and auto-
sampler temperatures were set at 30 ◦C and 25 ◦C, respectively. The
detection wavelength was 240 nm and an injection volume of 10 l
was used.
Samples were prepared by weighing approximately 1.00 g of
cream into a 50.0 ml  volumetric flask, adding 30 ml  of acetonitrile
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Table  1
Gradient elution programme.
Time (min) %A %B
START 18 82
16  48 52
25  90 10
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Fig. 2. Optimisation of the injection volume using a mixed standard solution: (a)
50  l, (b) 20 l and (c) 10 l. Chromatographic conditions as described in Table 1.
Peak assignment: PS (1), MP  (2), betamethasone (3), PP (4), BV (5), betamethasone-27  18 82
35  18 82
nd suspending by shaking in a water-bath at 65 ◦C. Thorough mix-
ng was ensured with the help of a vortexing machine. The resulting
uspension was shaken on a flat-bed shaker at approximately 200
hakes per minute and allowed to cool to room temperature before
eing made up to volume with acetonitrile. After 20 min  in a
reezer (−20 ◦C) a portion of the cold suspension was  centrifuged
t 3000 rpm for 5 min. The supernatant was removed and allowed
o warm to room temperature.
A portion of the supernatant was diluted 1–2 (v/v), e.g.
0.0–20.0 ml  with purified water. Finally, the solution was  filtered
hrough a 0.45 m regenerated cellulose filter (Macherey-Nagel,
ermany) into a suitable HPLC vial. The assay concentrations of
he standards were 200.0 and 12.14 g/ml for FA and BV and
0.0, 8.0 and 1.6 g/ml for PS, MP  and PP, respectively. These
oncentrations correspond to 100% of the label claim of each
omponent.
. Results and discussion
.1. Method development – optimisation of the gradient
rogramme, HPLC column, flow-rate and injection volume
Fusidic acid hemihydrate (see Fig. 1) has acidic character due
o the presence of a single carboxyl group with a pKa of 5.3 [2].
o achieve an acceptable retention of this compound on a C18 col-
mn, it needs to remain in its protonated form in solution, so that
t can interact with the stationary phase. Its retention is therefore
ffected by the pH of the mobile phase. Betamethasone-17-valerate
s well as methyl- and propylparaben are, on the other hand,
eutral compounds. The retention of these compounds should,
herefore, remain unaffected by the pH of the mobile phase. Since
otassium sorbate is the potassium salt of sorbic acid, it will be
resent in its ionised form in solution. The retention time of this
onised form will be influenced by the pH of the mobile phase. The
ompound will only be sufficiently retained on the HPLC column
n its protonated form, i.e. in the sorbic acid form which has a pKa
alue of 4.8 [14]. On consideration of the above points, an acidic
obile phase containing 10 g/l phosphoric acid (85%) and having
 pH of approximately 1.6 was chosen as mobile phase B. Mobile
hase A comprised of an 83:17 (v/v) mixture of acetonitrile and
ethanol.
For the initial experiments a Nucleosil C18 100-5,
50 mm × 4.6 mm ID column with 5 m particles was chosen.
he oven-temperature, detector wavelength and injection vol-
me  used were 25 ◦C, 240 nm and 50 l, respectively. The initial
onditions of the gradient programme were 40% mobile phase
 and 60% mobile phase B held for 10 min, after which the % of
 was increased to 100% over the next 30 min  and held at this
omposition for a further 10 min. After returning to the start
onditions over a period of 5 min  the system was  equilibrated for
 further 5 min  giving a total run time of 60 min. The flow rate was
.0 ml/min.The resolution between the peaks of potassium sorbate and
ethylparaben proved to be suboptimal during the initial tests.
he run time was also longer than desired for an RP-HPLC
ssay method. The gradient programme, oven-temperature and21-valerate (6), 3-didehydrofusidic acid (7) and FA (8).
flow-rate were optimised to reduce the run time. However, the
optimised method resulted in a co-elution of the potassium sor-
bate and methylparaben peaks. It was  found that increasing the
percentage of aqueous phase at the beginning of the gradient pro-
gramme  to 82% (v/v) enabled a complete baseline separation of both
peaks.
In gradient separations the column chemistry often plays a less
significant role than the changing chemistry of the mobile phase,
as compared to isocratic separations. Consequently, it is generally
possible in gradient separations to use shorter columns than for
isocratic separations because the theoretical plate count becomes
much less critical. In order to save mobile phase a shorter Ascentis
Express 100 mm × 3.0 mm ID column was  chosen in combination
with a mobile phase flow-rate of 0.75 ml/min. On  injecting 50 l
of a mixed standard solution, poor peak shape for the early elu-
ting compounds was observed due to overloading of the alternative
HPLC column, which had a smaller inner diameter than the initial
column. On reducing the injection volume from 50 l to 20 l and
then to 10 l a significant improvement of peak shape was observed
(Fig. 2).
The optimised gradient programme, stationary phase dimen-
sions, flow rate and injection volume allowed for a baseline
separation of all components (including the main degrada-
tion products of the APIs, betamethasone, betamethasone-21-
valerate, 3-didehydrofusidic acid, 16-epideacetylfusidic acid and
16-epideacetylfusidic acid-21,16-lactone) within 27 min, with a
further 8 min  equilibration time giving a total run time of
35 min.
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.2. Method validation
.2.1. Selectivity
The degradation pathways of betamethasone-17-valerate in
opical pharmaceutical preparations have been documented in
he literature [15,16]. Betamethasone-17-valerate undergoes an
ntra-molecular isomerisation under acidic and basic conditions
orming the more thermodynamically stable betamethasone-21-
alerate. Cleavage of the ester bond results in the alcohol base
etamethasone. Kinetic studies regarding these degradation pro-
esses indicate that the isomerisation step is dominant over
he hydrolysis reaction [17]. Betamethasone-21-valerate should,
herefore, be the dominant degradation product of betamethasone-
7-valerate in topical preparations at pH values around 5.0. This has
een confirmed through purity analysis with a separate analytical
rocedure.
Data regarding the stability of fusidic acid in finished formula-
ions or details on its potential degradation products do not appear
o be available in the literature. However, the current fusidic acid
emihydrate monograph of the European Pharmacopoeia (Ph.
ur.) [18] provides a list of possible impurities of the bulk API.
tudies performed by the authors using the above mentioned
urity method indicate that the impurities 3-didehydrofusidic
cid, 16-epideacetylfusidic acid and 16-epideacetylfusidic
cid-21,16-lactone are dominant degradation products of fusidic
cid in topical formulations incorporating this API. This data has
ot yet been published.
Potassium sorbate is known to degrade by oxidation in semi-
olid formulations due to the presence of air [19]. This process
akes place over a period of months and leads to the formation
f carbonyl compounds, such as propenal (acrolein) and mal-
naldehyde [20,21]. 4-Hydroxybenzoic acid alkyl esters such as
ethylparaben and propylparaben are generally stable at increased
emperature and at pH values below 6. Exposure to pH values at
r above 8 results in ester cleavage forming parahydroxy benzoic
cid [22]. There are currently no official requirements to detect
r quantify degradation products of preservative compounds in
harmaceutical preparations. In general, only preservatives may
e employed in drug products that have been shown to be safe
nd effective and whose degradation products are known to be
on-toxic at likely exposure levels. This is in contrast to API
ompounds whose degradation products must be detected and
uantified according to official requirements. Degradation prod-
cts of the preservative compounds have not been explicitly
onsidered during development and validation of this method,
.e. they have not been identified. The stability-indicating nature
f the method has been demonstrated by visual examination of
hromatograms from stressed samples (containing all likely degra-
ation products of both the APIs and preservatives), peak purity
nalysis of the analyte peaks using a diode-array-detector and
ass-balance analysis of the APIs from stability samples. This is
he standard approach found throughout the literature for assay
ethods.
Samples which had been stored under accelerated stability
onditions (40 ◦C/75% relative humidity) for 9 months as well as
amples stressed under oxidative-, light-stress and increased pH
onditions (pH 7) were measured. The oxidative- and light-stress
amples were generated by exposing samples of cream to air and
aylight for a period of 3 days. The pH stress-test was  performed
y adjusting the pH of the cream to 7 after manufacture and pla-
ing the cream on accelerated stability studies (40 ◦C/75% RH) for 6
onths.
As mentioned earlier, purity studies of the cream formula-ion with a separate procedure had previously demonstrated
hat the impurities betamethasone, betamethasone-21-valerate,
6-epideacetylfusidic acid and 16-epideacetylfusidic acid-21,Biomedical Analysis 96 (2014) 111–117
16-lactone are the dominant degradation products of the APIs. The
stressed samples were known to contain all of the above degra-
dation products at concentration levels significantly higher than
would be expected over the normal shelf-life of the pharmaceu-
tical product (24 months at 25 ◦C/60% relative humidity). Under
normal conditions the cream is stored in an aluminium tube which
is closed with an appropriate cap. This minimises exposure to light
and atmospheric oxygen during storage. The stressed samples were
therefore considered to be worst case.
Figs. 3 and 4 demonstrate that all relevant peaks are baseline
separated and there are no obvious interferences. The purity of each
of the analyte peaks was  evaluated using a photodiode array scan
from 200 to 400 nm.  Each of the five peaks of interest was found
to be pure with this method which demonstrates the stability-
indicating properties of the method. The mass-balance values of
the APIs for stability samples (see Tables 2 and 3) were calculated
by summing the assay values obtained with the present proce-
dure and the content values of relevant impurities obtained with
a separate purity method. The mass-balance values lie between
99.4% and 103.8% for stability samples (which had significantly
degraded) stored under intermediate (30 ◦C/65% relative humidity)
and accelerated (40 ◦C/75% RH) conditions. These values are accept-
able and further underline the stability-indicating nature of the
procedure.
3.2.2. Linearity
The linearity of the detector response for each of the five ana-
lytes was  checked using an 8-point-calibration over the range
50–150% of the theoretical concentration of each analyte in the
sample solution. The correlation coefficients of the best-fitting
lines obtained by least-squares regression were all >0.999. The
95% confidence interval of each of the y-intercepts contained the
value zero, justifying the use of a single-point standard calibra-
tion during routine analysis. The residual values demonstrated no
particular trend. A summary of the regression data is provided in
Table 4.
3.2.3. Precision and accuracy
The repeatability (reproducibility) of the analytical procedure
was checked by preparation and measurement of six sample solu-
tions by Analyst A using HPLC Machine A on Day 1. The relative
standard deviation (rsd) of the assay values for each of the analytes
were below 1.0%. The intermediate precision was  determined by
preparation and measurement of a further six samples by Analyst
B using HPLC Machine B on Day 2. The rsd values of a total of 12
measurements were also <1.0%.
The accuracy of the analytical procedure was determined by
preparation and measurement of 9 solutions comprising of placebo
which had been spiked with each of the compounds of interest
over the range 50–150% of the theoretical sample concentration.
The recovery rates for each component lay between 99.1% and
102.4%.
3.2.4. Solution stability and robustness of HPLC parameters
Solution stability was  determined by preparation of three
standard and three sample solutions (cream) and analyses of these
solutions at 3-hourly intervals over a period of 47 h. The solutions
were stored at 25 ◦C and protected from light. No degradation trend
was observed for any of the compounds of interest. The content val-
ues of relevant degradation products remained unchanged over the
measurement period.
In order to test the robustness of the method, the HPLC param-column temperature (±5 ◦C), flow-rate (±0.2 ml/min), volume of
acetonitrile in mobile phase A (±10 ml/l), volume of methanol
in mobile phase A (±10 ml/l), detection wavelength (±2 nm)  and
J. Byrne et al. / Journal of Pharmaceutical and Biomedical Analysis 96 (2014) 111–117 115
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Fig. 3. A chromatogram of topical cream after storage at 40 ◦C/75% relative humidity for 9 months. The HPLC conditions are the same as those provided in Table 1.  Peak
assignment: PS (1), MP  (2), PP (3), BV (4), degradant betamethasone-21-valerate (5) and FA (6).
Minutes
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34
V
o
lt
s
-0,02 5
0,00 0
0,02 5
0,050
0,07 5
0,10 0
0,12 5
0,15 0
0,17 5
0,20 0
0,22 5
0,25 0
0,27 5
0,30 0
1
2
3 4
5
6
7
8
Fig. 4. A chromatogram of a stressed sample (pH 7, 40 ◦C, 6 months) of topical cream showing relevant degradation products. The HPLC conditions are the same as those
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rovided in Table 1. Peak assignment: PS (1), MP  (2), PP (3), BV (4), degradant betam
6-epideacetylfusidic acid-21,16-lactone (8). The relative retention times of the 3 d
radient slope (±4%). Some of the conditions tested, e.g. increasing
he column-oven temperature by 5 ◦C lead to a reduced resolution
etween the potassium sorbate and methylparaben peaks. Conse-
uently, a resolution of at least 1.5 between both of these peaks has
een stipulated as a system suitability criterion.
able 2
tability data obtained under intermediate (30 ◦C/65% relative humidity) ICH stability con
30 ◦C/65% relative humidity 0 months 3 months 
Assay
Potassium sorbate 100.0 83.2 
Methylparaben 100.0 101.0 
Propylparaben 100.0 103.1 
Betamethasone-17-valerate 100.0 100.0 
Fusidic acid 100.0 101.5 
Degradation products of betamethasone-17-valerate
Betamethasone-21-valerate 0.87 1.25 
Sum  of all degradation products 0.96 1.25 
Mass-balance 101.0 101.3 
Degradation products of fusidic acid
3-Didehydrofusidic acid 0.33 0.36 
16-Epideacetylfusidic acid n.d. n.q. 
16-Epideacetylfusidic acid-21,16-lactone n.d. n.d. 
Sum  of all degradation products 0.33 0.36 
Mass-balance 100.3 101.8 one-21-valerate (5), degradant 16-epideacetylfusidic acid (6), FA (7) and degradant
ants are 0.93, 0.98 and 1.05 relative to fusidic acid.
3.3. Analysis of cream samplesDuring formulation development over 30 trial formulations
of topical cream were analysed. Many of the early formulations
proved to be highly unstable. With the aid of the developed assay
ditions over a 12-month storage period.
6 months 9 months 12 months Units
% relative to start
value
71.1 60.7 56.4
96.4 98.9 94.8
100.0 103.0 98.5
99.2 101.0 99.2
99.0 99.9 99.6
% (n.d. = not detected,
n.q. = not quantifiable)
1.90 2.69 3.08
2.00 2.82 3.08
101.2 103.8 102.3
0.38 0.38 0.40
n.q. 0.05 n.q.
0.06 0.05 0.07
0.44 0.48 0.47
99.4 100.4 100.1
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Table  3
Stability data obtained under accelerated (40 ◦C/75% relative humidity) ICH stability conditions over a 6-month storage period.
40 ◦C/75% relative humidity 0 months 3 months 6 months Units
Assay
% relative to start value
Potassium sorbate 100.0 90.4 89.3
Methylparaben 100.0 98.2 97.8
Propylparaben 100.0 100.0 100.6
Betamethasone-17-valerate 100.0 95.9 92.7
Fusidic acid 100.0 100.0 99.0
Degradation products of betamethasone-17-valerate
% (n.d. = not detected,
n.q. = not quantifiable)
Betamethasone-21-valerate 0.87 5.32 9.60
Sum  of all degradation products 0.96 5.32 9.75
Mass-balance 101.0 101.2 102.5
Degradation products of fusidic acid
3-Didehydrofusidic acid 0.33 0.37 0.37
16-Epideacetylfusidic acid n.d. 0.07 0.09
16-Epideacetylfusidic acid-21,16-lactone n.d. 0.12 0.21
Sum  of all degradation products 0.33 0.56 0.67
Mass-balance 100.3 100.6 99.7
Table 4
Regression data from the linearity experiments.
Substance y = mx + c r r2 Residuals 95% confidence
interval for y-intercept
Potassium sorbate y = 65,680x + 13,804 0.9999 0.9999 No trend c ± 16,944
Methylparaben y = 47,190x + 7311 0.9992 0.9984 No trend c ± 15,460
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Propylparaben y = 39,561x + 1108 
Betamethasone-17-valerate y = 24,520x + 2978 
Fusidic acid y = 6896x + 20,841 
rocedure it proved possible to determine that betamethasone-17-
alerate was isomerising rapidly to its corresponding 21-valerate
ster. This isomerisation process was shown to be dependent on
he pH of the aqueous phase of the cream as well as on the
torage temperature. Additionally, and quite surprisingly, the iso-
erisation rate was shown to be significantly influenced by the
oncentration of the primary emulsifier in the cream formulation.
t higher concentrations of emulsifier, e.g. 5%, the isomerisation
ccurs rapidly with 5% betamethasone-21-valerate being formed at
H 5.0 ± 0.2 after 3 months storage under the conditions 25 ◦C/60%
elative humidity. Reducing the emulsifier concentration leads to
 significant reduction of the isomerisation rate. After 3 months
torage under the conditions 25 ◦C/60% relative humidity and at
H 5.0 ± 0.2, only 0.1% betamethasone-21-valerate was observed
hen the emulsifier concentration was reduced to an appropriate
evel.
The data also indicated that the preservative compound, potas-
ium sorbate, degrades rapidly (Tables 2 and 3). Degradation of
otassium sorbate in semi-solid formulations is common and is
ot considered critical as long as it can be demonstrated that the
uantities present at the end of shelf-life are sufficient to ensure
icrobiological purity of the preparation. This can be investi-
ated by employing a test for efficacy of microbial preservatives
s described in any of the major pharmacopoeias. In contrast to
otassium sorbate, the API fusidic acid as well as the preserva-
ive compounds methyl- and propylparaben proved to be stable
nder real-time (25 ◦C/60% RH), intermediate (30 ◦C/65% RH) and
ccelerated (40 ◦C/75% RH) storage conditions. The results clearly
ndicate that the method is stability-indicating for the topical cream
reparation.
. ConclusionsA RP-HPLC method was developed to simultaneously determine
he content of fusidic acid, betamethasone-17-valerate, potassium
orbate as well as methyl- and propylparaben in a topical cream
reparation. The method was validated according to current ICH
[
[
2 0.9985 No trend c ± 2673
8 0.9997 No trend c ± 5486
8 0.9996 No trend c ± 28,059
guidelines and demonstrated to be selective, linear, precise, accu-
rate and robust within the validated range. The method has been
shown to be stability-indicating due to its ability to separate
the most important degradation products of the APIs and detect
changes of content of the active substances and preservatives over
the shelf-life of the pharmaceutical product.
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